Essec\Faculty\Model\Contribution {#2233
  #_index: "academ_contributions"
  #_id: "525"
  #_source: array:26 [
    "id" => "525"
    "slug" => "a-comparative-analysis-of-two-contrasting-european-approaches-for-rewarding-the-value-added-by-drugs-for-cancer-england-versus-france"
    "yearMonth" => "2014-05"
    "year" => "2014"
    "title" => "A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France"
    "description" => "DRUMMOND, M., PUYOU DE POUVOURVILLE, G., JONES, E., HAIG, J., SABA, G. et CAWSTON, H. (2014). A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France. <i>Pharmacoeconomics</i>, 32(5), pp. 509-520."
    "authors" => array:6 [
      0 => array:3 [
        "name" => "PUYOU DE POUVOURVILLE Gérard"
        "bid" => "B00072308"
        "slug" => "de-pouvourville-gerard"
      ]
      1 => array:1 [
        "name" => "DRUMMOND M."
      ]
      2 => array:1 [
        "name" => "JONES E."
      ]
      3 => array:1 [
        "name" => "HAIG J."
      ]
      4 => array:1 [
        "name" => "SABA G."
      ]
      5 => array:1 [
        "name" => "CAWSTON H."
      ]
    ]
    "ouvrage" => ""
    "keywords" => array:5 [
      0 => "National Health Service"
      1 => "Incremental Cost"
      2 => "Evidence Review Group"
      3 => "Technology Appraisal"
      4 => "Appraisal Committee"
    ]
    "updatedAt" => "2021-02-02 16:16:18"
    "publicationUrl" => "https://link.springer.com/article/10.1007%2Fs40273-014-0144-z"
    "publicationInfo" => array:3 [
      "pages" => "509-520"
      "volume" => "32"
      "number" => "5"
    ]
    "type" => array:2 [
      "fr" => "Articles"
      "en" => "Journal articles"
    ]
    "support_type" => array:2 [
      "fr" => "Revue scientifique"
      "en" => "Scientific journal"
    ]
    "countries" => array:2 [
      "fr" => null
      "en" => null
    ]
    "abstract" => array:2 [
      "fr" => "Within Europe, contrasting approaches have emerged for rewarding the value added by new drugs. In Ireland, The Netherlands, Sweden and the UK, the price of, and access to, a new drug has to be justified by the health gain it delivers compared with current therapy, typically expressed in quality-adjusted life-years (QALYs) gained. By contrast, in France and Germany, the assessment of added benefit is expressed on an ordinal scale, based on an assessment of the clinical outcomes as compared with existing care. This assessment then influences price negotiations. The objective of this paper is to assess the pros and cons of each approach, both in terms of the assessments they produce and the efficiency and practical feasibility of the process."
      "en" => "Within Europe, contrasting approaches have emerged for rewarding the value added by new drugs. In Ireland, The Netherlands, Sweden and the UK, the price of, and access to, a new drug has to be justified by the health gain it delivers compared with current therapy, typically expressed in quality-adjusted life-years (QALYs) gained. By contrast, in France and Germany, the assessment of added benefit is expressed on an ordinal scale, based on an assessment of the clinical outcomes as compared with existing care. This assessment then influences price negotiations. The objective of this paper is to assess the pros and cons of each approach, both in terms of the assessments they produce and the efficiency and practical feasibility of the process."
    ]
    "authors_fields" => array:2 [
      "fr" => "Management"
      "en" => "Management"
    ]
    "indexedAt" => "2024-12-22T16:21:42.000Z"
    "docTitle" => "A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France"
    "docSurtitle" => "Articles"
    "authorNames" => "<a href="/cv/de-pouvourville-gerard">PUYOU DE POUVOURVILLE Gérard</a>, DRUMMOND M., JONES E., HAIG J., SABA G., CAWSTON H."
    "docDescription" => "<span class="document-property-authors">PUYOU DE POUVOURVILLE Gérard, DRUMMOND M., JONES E., HAIG J., SABA G., CAWSTON H.</span><br><span class="document-property-authors_fields">Management</span> | <span class="document-property-year">2014</span>"
    "keywordList" => "<a href="#">National Health Service</a>, <a href="#">Incremental Cost</a>, <a href="#">Evidence Review Group</a>, <a href="#">Technology Appraisal</a>, <a href="#">Appraisal Committee</a>"
    "docPreview" => "<b>A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France</b><br><span>2014-05 | Articles </span>"
    "docType" => "research"
    "publicationLink" => "<a href="https://link.springer.com/article/10.1007%2Fs40273-014-0144-z" target="_blank">A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France</a>"
  ]
  +lang: "fr"
  +"_type": "_doc"
  +"_score": 9.275065
  +"parent": null
}